Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?

Bristol Myers BMY recently collaborated with Bain Capital to create a new independent biopharmaceutical company, which will be focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients.Bain Capital will make a $300 million funding in the new company, while BMY will out-license five immunology...